- Home
- HOUR vs ANL Comparison
HOUR vs ANL Comparison
Compare HOUR & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOUR
- ANL
- Stock Information
- Founded
- HOUR 2015
- ANL 2004
- Country
- HOUR United States
- ANL Cayman Islands
- Employees
- HOUR N/A
- ANL N/A
- Industry
- HOUR Catalog/Specialty Distribution
- ANL
- Sector
- HOUR Consumer Discretionary
- ANL
- Exchange
- HOUR Nasdaq
- ANL Nasdaq
- Market Cap
- HOUR 47.1M
- ANL 56.0M
- IPO Year
- HOUR 2022
- ANL 2023
- Fundamental
- Price
- HOUR $1.61
- ANL $1.55
- Analyst Decision
- HOUR
- ANL Hold
- Analyst Count
- HOUR 0
- ANL 1
- Target Price
- HOUR N/A
- ANL N/A
- AVG Volume (30 Days)
- HOUR 427.9K
- ANL 7.4K
- Earning Date
- HOUR 08-08-2025
- ANL 08-08-2025
- Dividend Yield
- HOUR N/A
- ANL N/A
- EPS Growth
- HOUR N/A
- ANL N/A
- EPS
- HOUR 0.01
- ANL N/A
- Revenue
- HOUR $139,408,829.00
- ANL N/A
- Revenue This Year
- HOUR N/A
- ANL N/A
- Revenue Next Year
- HOUR N/A
- ANL N/A
- P/E Ratio
- HOUR $234.09
- ANL N/A
- Revenue Growth
- HOUR 2.71
- ANL N/A
- 52 Week Low
- HOUR $0.83
- ANL $1.10
- 52 Week High
- HOUR $6.90
- ANL $4.10
- Technical
- Relative Strength Index (RSI)
- HOUR 62.63
- ANL 47.53
- Support Level
- HOUR $1.46
- ANL $1.50
- Resistance Level
- HOUR $1.74
- ANL $1.60
- Average True Range (ATR)
- HOUR 0.17
- ANL 0.07
- MACD
- HOUR 0.02
- ANL 0.02
- Stochastic Oscillator
- HOUR 35.59
- ANL 60.42
About HOUR Hour Loop Inc.
Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The Company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.